Circulating IL-6, Clusterin and Irisin in Obese Subjects
NCT ID: NCT04133896
Last Updated: 2019-10-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
176 participants
OBSERVATIONAL
2018-02-01
2019-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inflammation Regulation in Obese Patients
NCT01561664
Analyze the Relationship Between the Density of Fat Tissue and Cellulite With the Lumbar Lordosis Degree
NCT02903459
Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity
NCT01784289
Study of White Adipose Tissue Remodeling by Cryolipolysis in Humans
NCT04819321
Correlation of Irisin and Adipokine Levels With Body Mass Index and Risk Factors for Metabolic Syndrome in Hispanic Children
NCT02320110
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Method: This study was conducted on 176 non-diabetic subjects of both sexes. Participants were classified according to their sex into two groups; the male and female groups. The male group (88 men) was classified according to BMI into; group 1 (22 lean men), group 2 (22 class I obese men), group 3 (22 class II obese men), and group 4 (22 class III obese men). The female group (88 women) was also classified according to BMI exactly as the male group. Fasting blood glucose, fasting insulin, lipid panel, serum IL-6, clusterin and irisin levels were measured. One-way analysis of variance followed by Tukey's as post hoc test was used for comparison of variables.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 Male
group 1 (22 lean men),
IL-6, Clusterin, Irisin Level
Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
Group 2 Male
group 2 (22 class I obese men),
IL-6, Clusterin, Irisin Level
Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
Group 3 Male
group 3 (22class II obese men),
IL-6, Clusterin, Irisin Level
Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
Group 4 Male
group 4 (22 class III obese men).
IL-6, Clusterin, Irisin Level
Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
Group 1 Female
group 1 (22 lean women),
IL-6, Clusterin, Irisin Level
Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
Group 2 Female
group 2 (22 class I obese women),
IL-6, Clusterin, Irisin Level
Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
Group 3 Female
group 3 (22 class II obese women),
IL-6, Clusterin, Irisin Level
Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
Group 4 Female
group 4 (22 class III obese women).
IL-6, Clusterin, Irisin Level
Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IL-6, Clusterin, Irisin Level
Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age matched adult non-diabetic non-smoker males and females'
Exclusion Criteria
20 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Rehab Werida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rehab Werida
Clinical Pharmacy Lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rehab H Werida, Lecturer
Role: PRINCIPAL_INVESTIGATOR
Damanhour University, Faculty of Pharmacy
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University
Tanta, El-Gharbia, Egypt
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gouni-Berthold I, Berthold HK, Huh JY, Berman R, Spenrath N, Krone W, Mantzoros CS. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One. 2013 Sep 2;8(9):e72858. doi: 10.1371/journal.pone.0072858. eCollection 2013.
Baralla A, Sotgiu E, Deiana M, Pasella S, Pinna S, Mannu A, Canu E, Sotgiu G, Ganau A, Zinellu A, Sotgia S, Carru C, Deiana L. Plasma Clusterin and Lipid Profile: A Link with Aging and Cardiovascular Diseases in a Population with a Consistent Number of Centenarians. PLoS One. 2015 Jun 15;10(6):e0128029. doi: 10.1371/journal.pone.0128029. eCollection 2015.
van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med. 2013 May;71(4):174-87.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Obesity and IR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.